E-resources
PDF-
Frémond, Marie-Louise, MD; Rodero, Mathieu Paul, PhD; Jeremiah, Nadia, PhD; Belot, Alexandre, MD, PhD; Jeziorski, Eric, MD; Duffy, Darragh, PhD; Bessis, Didier, MD; Cros, Guilhem, MD; Rice, Gillian I., PhD; Charbit, Bruno, MSc; Hulin, Anne, PharmD, PhD; Khoudour, Nihel, MD; Caballero, Consuelo Modesto, MD; Bodemer, Christine, MD, PhD; Fabre, Monique, MD; Berteloot, Laureline, MD; Le Bourgeois, Muriel, MD; Reix, Philippe, MD; Walzer, Thierry, PhD; Moshous, Despina, MD, PhD; Blanche, Stéphane, MD, PhD; Fischer, Alain, MD, PhD; Bader-Meunier, Brigitte, MD; Rieux-Laucat, Fréderic, PhD; Crow, Yanick Joseph, MD, PhD; Neven, Bénédicte, MD, PhD
Journal of allergy and clinical immunology, 12/2016, Volume: 138, Issue: 6Journal Article
The patients, aged between 5 and 12 years, exhibited the phenotypic variability associated with TMEM173-activating mutations,2-4 with lung disease and systemic inflammation being the major features in patient 1 (P1) and patient 3 (P3), while in patient 2 (P2) skin involvement was most prominent (Fig 1; see Supplemental Text and Table E1 in this article's Online Repository at www.jacionline.org). Modest and incomplete downregulation of ISG was recently described in splenic B cells of mice treated with tofacitinib, a JAK1/3 inhibitor, with differential signaling effects suggesting currently poorly understood facets of IFN regulation.9 In this regard, our kinetic ex vivo experiments provide insights into the rapid dynamic changes in IFN signaling secondary to JAK1 blockade.
